2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1647

Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Safety and Efficacy in Open-Label, Long-Term Extension Studies over 8 Years
Abstract Number: 1643

Tofacitinib: Treatment Outcomes in Seropositive Versus Seronegative Patients in a Phase 3 RA Population
Abstract Number: 1661

Toll-like Receptor 4 Induced IL-20 and IL-24 Stimulate Osteoblast Mineralization and Are Increased in Spondyloarthritis
Abstract Number: 2300

Tophaceous Gout and the Risk of Mortality: A General Population-Based Study
Abstract Number: 2357

Topical Application of Aceclofenac Might NOT Produce a Significant Increase of Blood Pressure in Osteoarthritic Patients – a Continuous Automated Blood Pressure Monitor Study
Abstract Number: 3167

Total and Glucocorticoid-Related Damage Accrual in the Systemic Lupus International Collaborating Clinics Inception Cohort
Abstract Number: 1406

Towards Harmonized Data Collection in Rheumatoid Arthritis (RA): The EULAR Task Force for Standardizing a Minimum Data Collection for RA Observational Research
Abstract Number: 2196

Trajectories and Predictors of Fear-Avoidance in Persons with Rheumatoid Arthritis. a Longitudinal Observational Study
Abstract Number: 2273

Trans-Ancestral Meta-Analysis Identifies Nine New Loci Associated with Serum Uric Acid Concentrations
Abstract Number: 2138

Transcriptional Analysis of Synovial Tissue Reveals Sustained Inflammatory Chemokine Expression Despite Minimal Histopathologic Change in the Destabilization of Medial Meniscus Model of Murine Knee Osteoarthritis
Abstract Number: 1200

Transcriptional Profiling of Early RA Synovial Tissue Reveals the Impact of Triple DMARD Treatment on T Cell Activation Pathways
Abstract Number: 2455

Transcriptome Profile of Cells Isolated from a CHB Heart Support an Exuberant Inflammatory ⁄Pro-Fibrotic Cascade
Abstract Number: 2426

Transcriptomic Analysis of Immune Subsets in Juvenile Dermatomyositis before and after Treatment Identifies Novel Pathways Involved in Pathogenesis
Abstract Number: 96

Transforming Healthcare in Rheumatology: From Inpatient to Outpatient Care without Reductions in Healthcare Quality
Abstract Number: 1575

Transient Circulatory Existence of Multipotential Stromal Cells Is Unlikely to Contribute to the Pathogenesis of Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].